Japan's Meiji Seika Pharma has announced that Adcock Ingram Pharma Private, an affiliated company of Medreich has completed construction of a new manufacturing facility in Bengaluru, India, to enhance its production capacity of the contract manufacturing organisation (CMO) business.

With the construction cost of approx. JPY 2.21 billion, the new facility will start the commercial production from January 2024.

Adcock Ingram Pharma Private Limited, established in 2021, is a wholly-owned subsidiary of Adcock Ingram Limited that is a joint venture between Adcock Ingram Holdings Ltd., in South Africa, and Medreich Limited.

The new manufacturing facility has three floors above ground, a total floor area of 7,878 m², having an annual production capacity of 750 million tablets, 75 million sachets, and 4 million bottles, so that Adcock Ingram Pharma Private Limited can manufacture and supply pharmaceutical products not only for the Adcock Ingram Group in South Africa, but also for other clients.

The Meiji Group's Pharmaceutical Segment, in its "2023 Medium-Term Business Plan", has set an agenda to "Expand CMO/CDMO business" in its business strategies, in which Medreich Limited and Adcock Ingram Limited are regarded as the core companies of the CMO business.

The company will continue to optimise its production bases in Japan and overseas to strengthen production system and establish the one for stable supply of highly reliable pharmaceuticals and contribute to improving access to pharmaceuticals for people over the world.